Clinical characteristics of patients with recurrent Kawasaki disease: a nationwide cohort study of 19 456 patients with minimum 3-year follow up

被引:3
作者
Kim, Sin Young [1 ]
Shin, Ji Seong [1 ]
Jang, Min Sik [1 ]
Kim, Jihye [1 ,2 ]
机构
[1] Kangdong Sacred Heart Hosp, Dept Pediat, Div Infect, Seoul, South Korea
[2] Hallym Univ, Coll Med, Chunchon, South Korea
关键词
epidemiology; allergy and Immunology; infectious disease medicine; cardiology; EPIDEMIOLOGIC FEATURES; SOUTH-KOREA; JAPAN; CORTICOSTEROIDS; MANAGEMENT; TAIWAN;
D O I
10.1136/archdischild-2022-324467
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
ObjectiveTo identify the clinical characteristics of patients with recurrent Kawasaki disease (KD). DesignA nationwide, population-based, cohort study using the Korean National Health Insurance claims database between 2013 and 2016. PatientsA total of 19 456 patients under the age of 5 years who were diagnosed with initial episode of KD were included. A minimum follow-up period of 3 years was mandatory for inclusion. Main outcome measuresThe epidemiological and clinical profiles were compared between KD patients with and without recurrence. ResultsThe overall recurrence rate of KD was 3.84% (n=748), and the median interval to recurrence was 498 days (IQR: 257-860 days). Approximately 70% of all recurrences occurred within 2 years of the initial diagnosis. The annual proportions of recurrence were 40%, 28%, 18%, 8% and 4% from the first to the fifth year following the initial episode, respectively. Recurrence rates were significantly higher in patients aged <1 year than in those aged 4-5 years (4.65% vs 2.22%) and those who showed resistance to an initial dose of intravenous immunoglobulin (IVIG) (10.00% vs 3.18%). Allergic comorbidities and coronary artery complications at the initial episode were not associated with increased rates of recurrence. ConclusionsWe clearly identified the annual recurrence rates and their intervals from the initial episode according to the various factors identified, including young age and resistance to initial IVIG. Our results, based on a nationwide cohort, can be used as reference for follow-up management in patients with KD and in future studies.
引用
收藏
页码:307 / 312
页数:6
相关论文
共 32 条
  • [1] Corticosteroids Added to Initial Intravenous Immunoglobulin Treatment for the Prevention of Coronary Artery Abnormalities in High-Risk Patients With Kawasaki Disease
    Ae, Ryusuke
    Abrams, Joseph Y.
    Maddox, Ryan A.
    Schonberger, Lawrence B.
    Nakamura, Yosikazu
    Kuwabara, Masanari
    Makino, Nobuko
    Matsubara, Yuri
    Kosami, Koki
    Sasahara, Teppei
    Belay, Ermias D.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (17):
  • [2] Statistics Notes - Interaction revisited: the difference between two estimates
    Altman, DG
    Bland, JM
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2003, 326 (7382): : 219 - 219
  • [3] Rate, associated factors and outcomes of recurrence of Kawasaki disease in Ontario, Canada
    Chahal, Nita
    Somji, Zeeshanefatema
    Manlhiot, Cedric
    Clarizia, Nadia A.
    Ashley, Justin
    Yeung, Rae S. M.
    McCrindle, Brian W.
    [J]. PEDIATRICS INTERNATIONAL, 2012, 54 (03) : 383 - 387
  • [4] Epidemiologic features of Kawasaki disease in Taiwan, 1996-2002
    Chang, LY
    Chang, IS
    Lu, CY
    Chiang, BL
    Lee, CY
    Chen, PJ
    Wang, JT
    Ho, HN
    Chen, DS
    Huang, LM
    [J]. PEDIATRICS, 2004, 114 (06) : E678 - E682
  • [5] Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study
    de Abajo, Francisco J.
    Rodriguez-Martin, Sara
    Lerma, Victoria
    Mejia-Abril, Gina
    Aguilar, Monica
    Garcia-Luque, Amelia
    Laredo, Leonor
    Laosa, Olga
    Centeno-Soto, Gustavo A.
    Galvez, Maria Angeles
    Puerro, Miguel
    Gonzalez-Rojano, Esperanza
    Pedraza, Laura
    de Pablo, Itziar
    Abad-Santos, Francisco
    Rodriguez-Manas, Leocadio
    Gil, Miguel
    Tobias, Aurelio
    Rodriguez-Miguel, Antonio
    Rodriguez-Puyol, Diego
    [J]. LANCET, 2020, 395 (10238) : 1705 - 1714
  • [6] Management of Kawasaki disease
    Eleftheriou, D.
    Levin, M.
    Shingadia, D.
    Tulloh, R.
    Klein, N. J.
    Brogan, P. A.
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD, 2014, 99 (01) : 74 - 83
  • [7] FUJITA Y, 1989, PEDIATRICS, V84, P666
  • [8] Previous antibiotic use and the development of Kawasaki disease: a matched pair case-control study
    Fukazawa, Mitsuharu, Jr.
    Fukazawa, Mitsuru
    Nanishi, Etsuro
    Nishio, Hisanori
    Ichihara, Kiyoshi
    Ohga, Shouichi
    [J]. PEDIATRICS INTERNATIONAL, 2020, 62 (09) : 1044 - 1048
  • [9] Linking the Microoiota, Chronic Disease, anc the Immune System
    Hand, Timothy W.
    Vujkovic-Cvijin, Ivan
    Ridaura, Vanessa K.
    Belkaid, Yasmine
    [J]. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2016, 27 (12) : 831 - 843
  • [10] Hirata S, 2001, ACTA PAEDIATR, V90, P40, DOI 10.1080/080352501750064851